June 24, 2020 / 12:23 PM / 10 days ago

BRIEF-Rhythm Pharmaceuticals Announces Positive Results From Phase 2 Study Of Setmelanotide In Healthy Obese Volunteers

June 24 (Reuters) - Rhythm Pharmaceuticals Inc:

* RHYTHM PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 STUDY OF ONCE-WEEKLY FORMULATION OF SETMELANOTIDE IN HEALTHY OBESE VOLUNTEERS

* RHYTHM PHARMACEUTICALS INC - ONCE-WEEKLY FORMULATION OF SETMELANOTIDE ACHIEVED WEIGHT LOSS EFFICACY COMPARABLE TO DAILY-DOSING FORMULATION

* RHYTHM PHARMACEUTICALS INC - BOTH WEEKLY AND DAILY FORMULATIONS OF SETMELANOTIDE WERE OBSERVED TO BE SAFE AND WELL-TOLERATED

* RHYTHM PHARMACEUTICALS - PHARMACOKINETICS ANALYSIS SHOWED WEEKLY FORMULATION OF SETMELANOTIDE TROUGH DRUG CONCENTRATION SIMILAR TO DAILY FORMULATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below